NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
Rhea-AI Summary
NANOBIOTIX (Euronext: NANO / NASDAQ: NBTX) will be admitted to the CAC Mid 60 and SBF 120 indices on Euronext Paris, effective after market close on December 19, 2025. The company said the index inclusions follow Euronext Paris's annual review.
The announcement notes inclusion is expected to broaden visibility among institutional investors, strengthen the company’s presence in European equity markets, and increase exposure to index-linked investment strategies. Management framed the move as validation of the company’s long-term strategy as it advances late-stage clinical programs in physics-based oncology.
Positive
- Admitted to CAC Mid 60 and SBF 120 effective Dec 19, 2025
- Expected to broaden visibility among institutional investors
- Expected to increase exposure to index-linked investment strategies
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: REPL up 3.46%, ERAS up 5.88%, while ARCT and OPT are down 0.8% and 2.01%. With no consistent direction and no peers in the momentum scanner, NBTX trading appears stock-specific versus this index news.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 24 | Operational/financial update | Positive | +5.1% | Royalty financing and clinical/strategic progress highlighted in Q3 update. |
| Nov 14 | Capital structure update | Neutral | +2.6% | Disclosure of shares outstanding and voting rights under French rules. |
| Nov 13 | Platform advancement | Positive | +2.6% | Curadigm Nanoprimer IP expansion and new preclinical collaboration activities. |
| Nov 11 | Conference participation | Neutral | +3.1% | Jefferies London Healthcare Conference fireside chat announcement and webcast. |
| Nov 03 | Investor conferences | Neutral | -15.2% | Multiple investor conference appearances announced for week of Nov 10. |
Recent news, particularly operational and platform updates, often coincided with positive price reactions, while a multi-conference announcement saw a sharp decline, indicating occasional divergence on seemingly neutral items.
Over the past months, Nanobiotix issued several corporate updates. A Q3 2025 operational and financial update with a $50 million royalty financing, expected $21 million contingent payment, and cash visibility into early 2028 coincided with a 5.11% gain. Disclosures on voting rights and Curadigm Nanoprimer platform advancements each saw 2.61% moves. Conference participation news on Nov 11 was followed by a 3.13% rise, while a multi-conference participation announcement on Nov 3 preceded a -15.19% drop. Today’s index inclusion fits a pattern of visibility-enhancing corporate developments.
Market Pulse Summary
This announcement highlights Nanobiotix’s admission to the CAC Mid 60 and SBF 120 indices effective December 19, 2025, signaling increased visibility among European institutional investors and index-linked strategies. In recent months, the company paired financial updates, such as royalty financing and cash visibility extensions, with clinical and platform progress, often followed by notable price moves. Investors may monitor how expanded index presence interacts with upcoming clinical milestones and corporate developments when assessing risk and positioning.
Key Terms
index-linked investment strategies financial
AI-generated analysis. Not financial advice.
PARIS and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that following the annual review of the Euronext Paris indices, the Scientific Council of the Indices has decided to admit Nanobiotix to both the CAC Mid 60 and SBF 120 indices.
These changes will become effective after the market closes on Friday, December 19, 2025.
The CAC Mid 60 and SBF 120 indices represent two of the most widely followed benchmarks for mid-sized and leading listed companies in France. Inclusion in these indices is expected to broaden Nanobiotix’s visibility among institutional investors, strengthen the Company’s presence within European equity markets, and increase exposure to index-linked investment strategies.
“It is an honor to join the CAC Mid 60 and SBF 120 indices on Euronext Paris,” said Laurent Levy, Chief Executive Officer of Nanobiotix. “We believe this admission reflects the continued confidence of the financial markets in our long-term strategy and the disruptive potential of our nanotherapeutic solutions. As Nanobiotix advances toward key milestones and continues expanding the horizon of physics-based medicine, we remain focused on disciplined execution and creating sustainable value for patients, partners, and shareholders.”
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 25 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter
Disclaimer
This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceed therefrom, and the period of time through which the Company’s anticipates its financial resources will be adequate to support operations. Words such as “expects”, “intends”, “can”, “could”, “may”, “might”, “plan”, “potential”, “should” and “will” or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements which are based on the Company’ management’s current expectations and assumptions and on information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix’s business and financial performance, which include the risk that assumptions underlying the Company’s cash runway projections are not realized. Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix’s Annual Report on Form 20-F filed with the SEC on April 2, 2025 under “Item 3.D. Risk Factors”, in Nanobiotix’s 2024 universal registration document filed with the AMF on April 2, 2025 under “chapter 1.5 Risk Factors”, and subsequent filings Nanobiotix makes with the SEC and AMF from time to time, including the Half-Year Report at June 30, 2025 which are available on the SEC’s website at www.sec.gov and on the AMF's website at www.amf.org, The forward-looking statements included in this press release speak only as of the date of this press release, and except as required by law, Nanobiotix assumes no obligation to update these forward-looking statements publicly.
Contacts
| Nanobiotix | ||
| Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 joanne.choi@nanobiotix.com Ricky Bhajun Director, Investor Relations (EU) +33 (0) 79 97 29 99 investors@nanobiotix.com | |
| Media Relations | ||
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr | Global – uncapped Communications Becky Lauer +1 (646) 286-0057 nanobiotixteam@uncappedcommunications.com | |
Attachment
- 2025-12-15 -- NBTX -- Added to CAC Mid60 + SBF120 Indicies -- FINAL
FAQ
When will NANOBIOTIX (NBTX) join the CAC Mid 60 and SBF 120 indices?
Which indices will NANOBIOTIX (NBTX) be added to on Euronext Paris?
How might inclusion in CAC Mid 60 and SBF 120 affect NANOBIOTIX (NBTX) shareholders?
Does the announcement change NANOBIOTIX’s clinical development timeline?
What markets will NANOBIOTIX (NBTX) strengthen presence in after index inclusion?
Which NANOBIOTIX tickers are referenced in the index announcement?
